ALLRAllarity Therapeutics, Inc.
- GlobeNewswire
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 - ...
- GlobeNewswire
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environmentThe FDA requires that biomarker testing to select patients for registration trials must be ...
- GlobeNewswire
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the ...
- GlobeNewswire
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics with a Buy and raises the price target from $9.75 to $10.25. ...
- GlobeNewswire
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new intellectual property ...
- GlobeNewswire
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a ...
- GlobeNewswire
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancerSupports accelerating stenoparib toward FDA approval ...
- GlobeNewswire
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP ...
- SEC
S-3/A Form - [Amend] Registration statement under Securities Act of 1933 - Allarity Therapeutics, Inc. (0001860657) (Filer)
[Amend] Registration statement under Securities Act of 1933 ...
- GlobeNewswire
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
New AACR data highlight stenoparib's potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics with a Buy and raises the price target from $9.5 to $9.75. ...
- GlobeNewswire
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling ...
- GlobeNewswire
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as ...
- GlobeNewswire
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA ...
- GlobeNewswire
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. ...
- GlobeNewswire
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a ...
- GlobeNewswire
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - Allarity Therapeutics, Inc. (0001860657) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
EFFECT Form - Notice of Effectiveness - Allarity Therapeutics, Inc. (0001860657) (Filer)
Notice of Effectiveness ...
- SEC
424B3 Form - Prospectus [Rule 424(b)(3)] - Allarity Therapeutics, Inc. (0001860657) (Filer)
Prospectus [Rule 424(b)(3)] ...
- Analyst Upgrades
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics with a Buy and raises the price target from $9 to $9.25. ...
- SEC
S-3 Form - Registration statement under Securities Act of 1933 - Allarity Therapeutics, Inc. (0001860657) (Filer)
Registration statement under Securities Act of 1933 ...
- SEC
8-K Form - Current report, items 8.01 and 9.01 - Allarity Therapeutics, Inc. (0001860657) (Filer)
Current report, items 8.01 and 9.01 ...
- SEC
8-K Form - Current report, items 1.01, 3.02, and 9.01 - Allarity Therapeutics, Inc. (0001860657) (Filer)
Current report, items 1.01, 3.02, and 9.01 ...